Florida Reverses HIV Drug Cuts, But Gaps in the Safety Net Remain

TALLAHASSEE, FL – June 29, 2026 – A critical piece of Florida's public health infrastructure was pulled back from the brink today as Governor Ron DeSantis signed the state's 2026-27 budget, cementing the reversal of devastating cuts to the AIDS Drug Assistance Program (ADAP). The new budget, which locks in an additional $75 million in state funding for the program, marks a monumental victory for the tens of thousands of Floridians living with HIV who rely on the program for life-saving medication.

For months, patients and providers faced a crisis of uncertainty. Today, they can breathe a sigh of relief. "This victory belongs to our whole coalition, the clinicians, providers, and people living with HIV who told their stories at real personal cost," said Esteban Wood, Director of Advocacy and Legislative Affairs at the AIDS Healthcare Foundation (AHF), which spearheaded the campaign. "For months, it was a promise. Today it is the law, and people can finally breathe."

But while the core program has been restored, a closer look at the budget reveals that the network remains frayed. New constraints and unresolved policy gaps signal that the fight to secure a truly resilient healthcare safety net in Florida is far from over.

Anatomy of a Crisis

The crisis erupted in January 2026 when the Florida Department of Health (DOH) announced, with little warning, a series of drastic cuts to ADAP, citing a projected $120 million budget shortfall. The department slashed eligibility from 400 percent of the federal poverty level (FPL) down to just 130 percent—a drop from an annual income of roughly $62,600 to $20,345 for an individual. It also eliminated assistance for private insurance premiums and removed Biktarvy, the nation's most prescribed HIV medication, from its formulary.

The impact was immediate and catastrophic. Over 12,000 people, with some estimates climbing as high as 16,000, lost their coverage in March. Many were left with the impossible choice of rationing medication or going without it altogether, risking not only their own health but also the public health principle of "Treatment as Prevention," which holds that virally suppressed individuals cannot transmit HIV.

In response, AHF mobilized a broad coalition, launching a multi-front campaign that combined legal action, intense lobbying in both legislative chambers, rallies at the state Capitol, and a statewide awareness campaign. The foundation sued the state, arguing the DOH had failed to follow proper rule-making procedures. When the department countered with an emergency rule to formalize the cuts, the fight moved squarely into the political arena. The powerful personal testimony from people living with HIV proved pivotal, putting a human face on the bureaucratic decision and galvanizing lawmakers. Their pressure resulted in a unanimous, bipartisan vote in March for a $30.9 million emergency bridge to temporarily restore services until the new fiscal year began.

A Lifeline Restored, With Conditions

Effective July 1, ADAP will return to its former strength. Eligibility is restored to 400 percent FPL, and the full medication formulary, including Biktarvy, is back. This reversal is a direct result of the relentless advocacy that reframed the debate from a simple budget line item to a fundamental public health imperative.

However, tucked within the budget is a new and significant limitation: a hard cap of 21,000 people on direct dispense enrollment. This part of the program primarily serves uninsured individuals who receive medications directly through the state's pharmacy network. While AHF welcomed the funding restoration, it staunchly opposes the cap on principle, arguing that no one who needs life-saving medicine should ever be turned away.

The cap introduces a critical vulnerability into the system. Data from March 2026, when the temporary stopgap was passed, projected that 23,031 individuals would need to utilize the direct dispense program. If those numbers hold, the 21,000-person limit creates a potential shortfall of over 2,000 slots, threatening to create a new waitlist and another crisis just as the last one has been resolved. This arbitrary limit on a vital network undermines the very concept of a public health safety net, which must be able to expand to meet demand.

The Unfinished Fight for a Complete Network

Beyond the enrollment cap, another crucial component of the ADAP infrastructure was left on the cutting room floor: insurance premium assistance. The new budget did not restore the program that helped low-income individuals maintain their private insurance coverage. This assistance was a fiscally prudent mechanism; by keeping people on private plans, the state could collect significant manufacturer rebates that, in turn, helped fund the entire ADAP system. Advocates argue that the program more than paid for itself.

Without this support, patients must now cover their own premiums or lose their insurance, potentially forcing more people onto the direct dispense program and adding pressure to its new enrollment cap. Community organizations are attempting to fill the void, but this often means diverting funds from other essential services. The next flashpoint in this debate is set for January 2027, when an independent state review of the premium assistance program is due. Advocates are already preparing to use its findings to press for a full restoration.

This battle also casts a harsh light on the root cause of the budget pressures: the exorbitant cost of pharmaceuticals. The lifetime cost of HIV treatment can exceed $420,000 per person, placing immense strain on public programs. AHF and its allies are now turning their attention back to the manufacturers. "The cuts are reversed, but the fight is not over," Wood stated. "Premium assistance still has to come back, and the companies that set these prices still have to answer for them."